InterAx, a Biotech company pioneering computational pharmacology for drug discovery, has closed a financing round of CHF 3 million. The investment round was led by Falcon III Ventures and investiere. The new funds will be used to accelerate commercialization of the technology platform which enables intelligent drug candidate design and selection. InterAx appoints Dr. Bettina Ernst as a new member of the board of directors. She brings in additional extensive and valuable experience from the biotech and pharmaceutical industry.

Third biotech company financed by investiere

“InterAx’ technology promises to become an important tool for the pharma industry in its endeavor to find new drugs”, says Romeo Bütler, investment manager at investiere. As a result of InterAx funding round, investiere has already financed three biotech companies. This is a sign that investiere has a large base of sophisticated investors with an appetite for the biotech sector. For that reason, investiere will continue to actively look for promising investment opportunities in biotech.

InterAx Biotech AG
InterAx is uniquely positioned to assist GPCR drug candidate design and selection by integrating bioanalytical and computational pharmacology in collaborative projects with Biotech and Pharma companies. InterAx applies mathematical models and simulations to in house-derived bioanalytical data in order to address the complexity of drug-induced cellular signaling mechanisms. Our goal is to close the gap between laboratory experiments and in vivo studies by streamlining the critical processes of drug candidate design and selection, thereby significantly reducing the risks, costs and duration of drug discovery and development of new drugs.